Home / Going-concern warnings / BioXcel Therapeutics, Inc.
Filed 2025-05-12 路 Form 10-Q 路 Accession 0001558370-25-007269 nano
Price before filing: $1.53 (2025-05-09 close, split/dividend-adjusted)
Market cap at flag: $11.6M (2025-05-12) 路 Latest: $549,360 (2026-10-01)
| Window | BTAI | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +17.0% | +6.6% | +10.4% | 2025-06-11 |
| 90 days | +318.3% | +13.0% | +305.3% | 2025-08-11 |
| 180 days | +26.1% | +21.4% | +4.7% | 2025-11-10 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"Based on our existing cash, cash equivalents and lack of current availability under our funding facilities, we do not believe we have sufficient cash on hand to support current operations and service our debt obligations for at least one year from the date of issuance of the audited consolidated financial statements appearing in this Quarterly Report on Form 10-Q. This condition raises substantial doubt about our..."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-03-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.